Key result
TAVR matches SAVR overall in low-risk patients despite reducing 30-day mortality ~40%.
Why the study?
Although TAVR has gained preference over SAVR in clinical practice, there is a dearth of comprehensive research directly comparing their real-world outcomes.
Does TAVR improve or reduce mortality and complications compared to SAVR in patients with aortic stenosis, particularly those at low surgical risk?
Does TAVR improve or reduce mortality and complications compared to SAVR in patients with aortic stenosis, particularly those at low surgical risk?
This narrative review highlights that TAVR is a favorable and comparable alternative to SAVR in low-risk patients with severe aortic stenosis, though it carries distinct risks such as increased need for pacemakers.
Supports TAVR-SAVR equivalence in low-risk aortic stenosis; leaves open long-term durability and pacemaker risks for prospective trials.
"Aortic stenosis" (AS) refers to a cardiac condition in which the aortic valve narrows, creating an obstruction that hinders the flow of blood from the left ventricle to the aorta. This contraction of the arteries influences normal blood circulation, leading to elevated pressure within the left ventricle and potentially culminating in heart failure. The management of AS typically involves two primary treatments, i.e. "surgical aortic valve replacement" (SAVR) and "transcatheter aortic valve replacement" (TAVR). In both cases, the goal is to replace a dysfunctional aortic valve with a functional substitute. Presently, TAVR has gained much preference over SAVR in clinical practice. However, there is a dearth of comprehensive research directly comparing the real-world outcomes of TAVR and SAVR. In recent years, TAVR has emerged as an attractive alternative to SAVR, yet studies that provide a detailed comparison of their real-world solutions are limited. This review article assesses the mortality of patients who underwent TAVR vis-a-vis patients who underwent SAVR.
No takes yet. Share an insight, caveat, or question.
Topalkatti et al. (2023) conducted a review in Aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve replacement exhibits similar overall effectiveness to surgical replacement in low-risk patients, though it reduced 30-day mortality by 40.1% in one included meta-analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: